Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
Corominas Argente del Castillo, Josep (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Sapena, Victor (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Sanduzzi Zamparelli, Marco (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Millán, Cristina (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Samper, Esther (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Llarch, Neus (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Iserte, Gemma (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Torres, Ferran (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Da Fonseca, Leonardo G. (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Muñoz-Martínez, S (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Forner, Alejandro (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Bruix, Jordi (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Boix, Loreto (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Reig, María (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))

Fecha:	2021
Resumen:	Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. These events are possibly immune-related. Therefore, we analyzed the phenotype of 52 sorafenib-treated patients' circulating lymphocytes throughout treatment. We found that different co-stimulatory and immune exhaustion markers, such as Programmed cell death protein 1 (PD-1) and DNAX accessory molecule 1 (DNAM-1) amongst others, correlate with the probability of developing these adverse events, both before and during the treatment. We also compared the phenotype of those lymphocytes expressing DNAM-1 with those that do not, and while NK DNAM-1-expressing cells have a co-stimulatory phenotype, T DNAM-1-expressing cells are immune-suppressors. Overall, we set a rationale for the combination of sorafenib and immune-targeted therapies; and for the use of immune markers (such as DNAM-1) for patients' prognosis evaluation. Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1 + cells express activation markers, T DNAM-1 + cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.
Ayudas:	Instituto de Salud Carlos III FI19/00222 Instituto de Salud Carlos III PI18/0768 Ministerio de Economía y Competitividad PI15/00145 Instituto de Salud Carlos III PI18/00358 Instituto de Salud Carlos III PI18/00542
Nota:	Altres ajuts: Asociación Española Contra el Cáncer PI044031
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Hepatocellular carcinoma ; Sorafenib ; Early dermatologic adverse events ; Peripheral blood mononuclear cells ; Immune cell phenotyping ; PD-1 ; DNAM-1 ; CD96
Publicado en:	Cancers, Vol. 13 (january 2021) , ISSN 2072-6694

DOI: 10.3390/cancers13030426
PMID: 33498698

20 p, 2.2 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados